Glioblastoma (newly diagnosed or recurrent; combo with active agents) | XPORT-GBM-029
Indication: newly diagnosed or recurrent; combo with active agents
Title: Glioblastoma (newly diagnosed or recurrent; combo with active agents) | XPORT-GBM-029
Drug: selinexor
Please visit clinicaltrials.gov for more information about this study
This trial is for selinexor.
Phase 1 | Phase 2 | Phase 3 | Commercial |
---|---|---|---|
Phase 1 | Phase 2 | Phase 3 | Commercial |